Novel molecular pathways in Gorham disease: implications for treatment
Jeroen Hagendoorn1, Torunn I Yock, Inne H M Borel Rinkes
1Department of Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pediatric Blood & Cancer
|November 12, 2013
Summary
Gorham disease, a rare lymphatic proliferation causing bone loss, lacks standard treatments due to limited research. Understanding lymphangiogenesis may reveal new therapeutic targets for this devastating condition.
Area of Science:
- Oncology
- Rare Diseases
- Lymphatic Biology
Background:
- Gorham disease is a rare neoplastic proliferation of lymphatic vessels.
- It is characterized by osteolysis and can be fatal.
- Limited clinical expertise and trial data hinder treatment development.
Purpose of the Study:
- To review current understanding of Gorham disease pathophysiology.
- To discuss established and emerging therapeutic strategies.
- To propose a rationale for treatment approaches.
Main Methods:
- Literature review of Gorham disease.
- Analysis of recent findings in lymphangiogenesis.
- Synthesis of existing and novel treatment strategies.
Main Results:
- Gorham disease pathophysiology is poorly understood.
- Standardized treatments are unavailable.
- Emerging knowledge of lymphangiogenesis offers potential therapeutic insights.
Conclusions:
- Further research into Gorham disease mechanisms is crucial.
- Targeting lymphangiogenesis may provide novel treatment avenues.
- A structured treatment rationale is needed for clinical management.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:24Graves Disease II: Pathophysiology
33
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
33
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
01:30Pulmonary Hypertension: Classification and Pathogenesis
911
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
911
01:21Huntington Disease l: Introduction
166
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
166
01:19Cushing Syndrome II: Pathophysiology
56
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
56